Comparison · NCT02196324-sae
Serlopitant vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Serlopitant vs Placebo: serious adverse events. Trial comparisons, record NCT02196324-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02196324-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0469 | 0.0161 | 0.129 | wilson | |
| Risk in group 2 | 0.0317 | 0.00875 | 0.109 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0151 | -0.0676 | 0.1 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.48 | 0.255 | 8.54 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.242 | 9.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Serlopitant than on Placebo | 66.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Serlopitant | Randomized participants took Serlopitant 5 mg tablets for oral administration at a loading dose of 3 tablets at baseline (Day 1) followed by 1 tablet every day at bedtime for 8 weeks. | 3 | 64 | EG001 |
| Group 2 | Placebo | Randomized participants took matching placebo tablets for oral administration as 3 tablets at baseline (Day 1) followed by 1 tablet every day at bedtime for 8 weeks. | 2 | 63 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the time of informed consent (Screening) until the last study visit (follow-up phone call, Week 10).
Source ClinicalTrials.gov
Trial
- Title
- A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
- NCT number
- NCT02196324
- Phases
- PHASE2
- Conditions
- Prurigo Nodularis
- Interventions
- serlopitant, Placebo
- Lead sponsor
- Vyne Therapeutics Inc.
- Results first posted
- 2021-02-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02196324?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02196324-sae